UPDATE : Friday, June 5, 2020
HOME Pharma
Hanmi unveils research results for Rosuzet and Amosartan Plus
  • By Lee Han-soo
  • Published 2018.09.05 16:14
  • Updated 2018.09.05 16:14
  • comments 0

Hanmi Pharmaceutical has presented research results on Rosuzet and Amosartan Plus, its dyslipidemia and hypertension treatments, respectively, in a meeting at the Korean Society of Lipid and Atherosclerosis (KSoLA).

The meeting, held last Friday, offered two presentation sessions, each given by Professor Kim Heon-sung from Catholic University of Korea’s College of Medicine, and Professor Park Kyung-il from the Dong-A University’s College of Medicine.

Professor Kim presented his research on “Real world evidence; The benefits of intensive lipid-lowering therapy,” and Professor Park gave a speech on “Evidence-based approach for intensive blood pressure control.”

“Recently, the dyslipidemia guideline recommends lowering LDL-cholesterol (LDL-C),” Prof. Kim said. “However, as statin monotherapy has limits in treating patients, statin/ezetimibe combo treatment such as Rosuzet has become an alternative.”

Kim then offered real-world research based on 35,000 patient’s electronic medical records (EMR) data.

“The research showed that Rosuzet effectively lowered LDL-C, regardless of the former drugs used by patients,” he said. “This study is meaningful as it is the first real-world data on LDL-C-lowering effects of a statins/ezetimibe combo treatment in large-scale patients.”

Professor Park mentioned the need for aggressive blood pressure control in high-risk patients.

“In recent years, U.S., EU and domestic guidelines have recommended cardiovascular risk management through more active blood pressure control.” Prof. Park said. “Amosartan Plus is a three-drug combination, which contains chlorthalidone, a diuretic that has been proven to reduce cardiovascular disease.”

Therefore, a stronger coercion effect can be expected in high-risk patients who do not respond well to active blood pressure control and two-drug combination treatments, he added.

The Dong-A University professor also said, “Since a calcium channel blocker (CCB)/angiotensin receptor blocker (ARB) combo therapy has become the main treatment strategy in Korea, there is a need for an alternative treatment.”

The ideal combination would be a CCB/ARB/chlorthalidone combo treatment such as Amosartan Plus, he added.


<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Han-soo
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top